登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由哈尔滨医科大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07752550,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 100 岁;性别:仅女性
登记记录的入选字段
Available tissue sample for testing, and gBRCA1/2 mutation status must be determined prior to treatment;
入选标准第 7 条
Received other anti-tumor therapy within 4 weeks prior to the first dose of study drug;
排除标准第 2 条
Prior treatment with tumor immunotherapy (including but not limited to PD-1, PD-L1, CTLA-4 inhibitors, etc.) or TGF-β inhibitors;
排除标准第 3 条
Prior treatment with PARP inhibitors (except for patients who completed PARP inhibitor therapy for ovarian cancer ≥5 years ago with no recurrence or metastasis);
排除标准第 4 条
Underwent major surgery unrelated to breast cancer within 4 weeks prior to enrollment, or have not fully recovered from such surgery;
排除标准第 6 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
入选标准第 6 条
At least one measurable lesion per RECIST version 1.1 criteria;
入选标准第 3 条
Congenital or acquired immunodeficiency (e.g., HIV-infected patients);
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07752550,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years, female; Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage <1%), PR-negative (IHC PR-positive percentage <1%), and HER2-negative (IHC -/+ or IHC ++ but FISH/CISH -); At least one measurable lesion per RECIST version 1.1 criteria; Advanced cohort: Life expectancy ≥3 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Available tissue sample for testing, and gBRCA1/2 mutation status must be determined prior to treatment; Adequate major organ function meeting the following criteria (no blood transfusion or use of granulocyte colony-stimulating factor or thrombopoietin within 2 weeks prior to screening): Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use adequate contraception during the study period and for at least 4 months after the last dose of study drug; Willing to participate, capable of providing signed informed consent, and compliant with study procedures.排除标准:Exclusion Criteria:
Concurrently receiving anti-tumor therapy in another clinical trial; Received other anti-tumor therapy within 4 weeks prior to the first dose of study drug; Prior treatment with tumor immunotherapy (including but not limited to PD-1, PD-L1, CTLA-4 inhibitors, etc.) or TGF-β inhibitors; Prior treatment with PARP inhibitors (except for patients who completed PARP inhibitor therapy for ovarian cancer ≥5 years ago with no recurrence or metastasis); Untreated active brain metastases or leptomeningeal metastases; Underwent major surgery unrelated to breast cancer within 4 weeks prior to enrollment, or have not fully recovered from such surgery; Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilator therapy for medical intervention are excluded; Severe cardiac disease or conditions, including but not limited to: documented history of heart failure or systolic dysfunction (LVEF <50%); uncontrolled high-risk arrhythmias, such as atrial tachycardia, resting heart rate >100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia), or high-grade atrioventricular block (i.e., Mobitz II second-degree or third-degree atrioventricular block); angina requiring anti-anginal medication; clinically significant valvular heart disease; ECG showing transmural myocardial infarction; poorly controlled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg); Congenital or acquired immunodeficiency (e.g., HIV-infected patients); Received live vaccine within 4 weeks prior to study drug administration or likely to receive such vaccine during the study period; Known hypersensitivity to any component of the study drugs in this protocol; Severe concomitant disease or other comorbidities that may interfere with the planned treatment, or any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07752550, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07752550,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。